FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
19/02/2026
Voltar para busca
Dado oficial do USPTO
LIVESPO A FUTURE WITHOUT ANTIBIOTICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
31
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
30/11/2023
Data de registro
06/05/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
06/05/2025
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
99
Localização do titular
VN
Examinador
CORWIN, KEVIN SCOTT
Unidade examinadora
M30
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of the stylized wording LIVESPO with the wording LIVE being in grey and SPO being in dark blue. Below this wording appears the smaller stylized wording A FUTURE WITHOUT ANTIBIOTICS in grey. All the aforementioned appears on a white background.
Titulares e representantes
Titulares
LIVESPO GLOBAL JOINT STOCK COMPANY
Representantes
Christopher Bennett Technology Innovation Law, LLC
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceuticalspharmaceutical preparations for supportive treatment and prevention of intestinal diseasesincluding dysbiosis in the nature of imbalanced microbiotainflammatory bowel disease (IBD)irritable bowel syndrome (IBS)diarrheaconstipationanorexiaunderweight; Pharmaceuticalspharmaceutical preparations for supportive treatment and prevention of respiratory diseasesrunny nosenasal congestionallergic rhinitiscoughrespiratory infections caused by RSV and influenza virus; Pharmaceuticalspharmaceutical preparations for supportive treatment and prevention of dental diseasesincluding tooth decay and periodontitis; Pharmaceuticalspharmaceutical preparations for supportive treatment and prevention of vaginal disorderssuch as itchingirritationunpleasant odorabnormal dischargediscoloration of vaginal secretions; Pharmaceuticalspharmaceutical preparations for supportive treatment and prevention of skin diseasesincluding mild to moderate acneoily skinatopic dermatitis; Dietetic foods adapted for medical use; Bio-products for medical purposesbiological preparations for the treatment of supportive treatment and prevention of intestinal diseasesincluding dysbiosis in the nature of imbalanced microbiotainflammatory bowel disease (IBD)irritable bowel syndrome (IBS)diarrheaconstipationanorexiaunderweight; Bio-products for medical purposesbiological preparations for the treatment of supportive treatment and prevention of respiratory diseasesrunny nosenasal congestionallergic rhinitiscoughrespiratory infections caused by RSV and influenza virus; Bio-products for medical purposesbiological preparations for the treatment of supportive treatment and prevention of dental diseasesincluding tooth decay and periodontitis; Bio-products for medical purposesbiological preparations for the treatment of supportive treatment and prevention of vaginal disorderssuch as itchingirritationunpleasant odorabnormal dischargediscoloration of vaginal secretions; Bio-products for medical purposesbiological preparations for the treatment of supportive treatment and prevention of skin diseasesincluding mild to moderate acneoily skinatopic dermatitis
Publicações
Histórico de despachos e eventos da marca no USPTO.
31 publicações encontradas
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
02/12/2025
XXCR
GENERIC MADRID TRANSACTION CREATED
01/12/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
12/09/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
27/08/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
27/08/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/08/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/05/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
06/05/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
18/03/2025
PUBO
PUBLISHED FOR OPPOSITION
18/03/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/03/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
21/02/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/02/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/02/2025
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
20/02/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
12/02/2025
GNFR
FINAL REFUSAL E-MAILED
12/02/2025
CNFR
FINAL REFUSAL WRITTEN
12/02/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
23/01/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/01/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
23/01/2025
RFNT
REFUSAL PROCESSED BY IB
17/08/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
29/07/2024
RFRR
REFUSAL PROCESSED BY MPU
29/07/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
29/06/2024
CNRT
NON-FINAL ACTION WRITTEN
28/06/2024
DOCK
ASSIGNED TO EXAMINER
27/06/2024
MAFR
APPLICATION FILING RECEIPT MAILED
05/04/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/04/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
28/03/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace LIVESPO A FUTURE WITHOUT ANTIBIOTICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.